Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506111 | 0.80 | LMNA (0.43) | MEN1GFERKMT2ALMNAALDH1A1 | |
| SCHEMBL4504259 | 0.78 | RIPK1 (0.47) | MEN1GFERKMT2ALMNAALDH1A1 | |
| SCHEMBL4509306 | 0.77 | HTR3A (0.44) | MEN1GFERKMT2A | |
| SCHEMBL4509314 | 0.76 | HTR3A (0.42) | MEN1GFERKMT2A | |
| SCHEMBL4500070 | 0.75 | CXCR4 (0.53) | LMNAALDH1A1ACHECXCR4TP53 | |
| SCHEMBL4496934 | 0.74 | MEN1 (0.46) | MEN1GFERKMT2ALMNAALDH1A1 | |
| SCHEMBL4502209 | 0.74 | MEN1 (0.42) | MEN1GFERKMT2ALMNAALDH1A1 | |
| SCHEMBL4501344 | 0.71 | OPRM1 (0.51) | MEN1KMT2AACHE | |
| SCHEMBL4502894 | 0.70 | ACHE (0.60) | ACHECXCR4 | |
| SCHEMBL4502250 | 0.70 | ACHE (0.48) | MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MEN1 3556/4885GFER 4667/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.